Yong Rong (HK) Asset Management’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-130,000
Closed -$6.06M – 8
2021
Q4
$6.06M Buy
130,000
+100,249
+337% +$5.09M 4.79% 9
2021
Q3
$1.5M Buy
+29,751
New +$1.24M 0.99% 13
2021
Q2
– Sell
-198,312
Closed -$5.76M – 19
2021
Q1
$5.76M Hold
198,312
– – 1.58% 11
2020
Q4
$5.58M Buy
198,312
+153,312
+341% +$4.41M 1.5% 9
2020
Q3
$1.39M Buy
+45,000
New +$1.52M 0.95% 9

Other funds holding LEGN

Yong Rong (HK) Asset Management's LEGN Position: Q1 2022 in Review

Yong Rong (HK) Asset Management sold out of Legend Biotech (LEGN) in Q1 2022, closing a stake of 130,000 shares — an estimated $6.06M sold.

Yong Rong (HK) Asset Management first reported a position in LEGN in Q3 2020 and held it in 5 quarters. The position peaked at $6.06M in Q4 2021. 141 funds tracked by Wall St. Rank hold LEGN as of Q1 2022.

  • Yong Rong (HK) Asset Management reported no remaining Legend Biotech position as of Q1 2022 after selling out during the quarter.
  • Yong Rong (HK) Asset Management sold 130,000 Legend Biotech shares in Q1 2022, an estimated $6.06M.
  • Yong Rong (HK) Asset Management first reported a position in Legend Biotech in Q3 2020 and held it in 5 quarters.
  • Yong Rong (HK) Asset Management's Legend Biotech position peaked at $6.06M in Q4 2021.
  • 141 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2022.

Based on Yong Rong (HK) Asset Management's 13F filing for Q1 2022, filed 4 May 2022.